Copertina

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Andrea Martini, Patrizia Pontisso
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed
di: Haibo Jing, et al.
Pubblicazione: (2024)

Letter: Fibrates may be safe and effective in patients with primary biliary cholangitis and decompensated cirrhosis—Authors' reply
di: Lukas Burghart, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—an emulated clinical trial. Authors' reply
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply
di: Sagnik Biswas, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients—Authors' reply
di: Linda Henry, et al.
Pubblicazione: (2024)

Terlipressin therapy is associated with increased risk of colonisation with multidrug‐resistant bacteria in patients with decompensated cirrhosis
di: Marcus M. Mücke, et al.
Pubblicazione: (2024)

Letter: Bisphosphonate effectiveness in patients with cirrhosis—An emulated clinical trial
di: Mingsi Zhang, et al.
Pubblicazione: (2024)

Impact of non‐selective beta blockers on further decompensation and death in decompensated cirrhosis: Benefit and risk stratification by MELD score
di: Ting Wang, et al.
Pubblicazione: (2024)

Editorial: Non‐selective beta‐blockers: A lifesaving shield for critically ill patients with acute decompensation of cirrhosis?
di: Ling Yang, et al.
Pubblicazione: (2024)

Letter: Use of liver stiffness measurement to identify liver cirrhosis in patients with chronic hepatitis D
di: Jian Wang, et al.
Pubblicazione: (2024)

Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find
di: Leya Nedumannil, et al.
Pubblicazione: (2024)

Bisphosphonate effectiveness in patients with cirrhosis: An emulated clinical trial
di: Elliot B. Tapper, et al.
Pubblicazione: (2024)

Editorial: Revisit the causes and long‐term outcomes in cirrhosis patients
di: Ming‐Lun Yeh, et al.
Pubblicazione: (2024)

Review article: Evaluation and care of the critically ill patient with cirrhosis
di: Iva Kosuta, et al.
Pubblicazione: (2024)

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
di: Senlin Ye, et al.
Pubblicazione: (2024)

Letter: Impact of antiviral treatment on renal function in patients with chronic hepatitis B—Author's reply
di: Hyeyeon Hong, et al.
Pubblicazione: (2024)

Letter: Irritable bowel syndrome and antibiotics—Authors' reply
di: Kyle Staller, et al.
Pubblicazione: (2024)

Letter: Association between terlipressin and multidrug‐resistant organism rectal colonization: Authors' reply
di: Marcus M. Mücke, et al.
Pubblicazione: (2024)

Editorial: Novel insights into the prognostic relevance of high‐dose PPI treatment in patients with cirrhosis
di: Dominik Bettinger, et al.
Pubblicazione: (2024)

Letter: Bif195 for aspirin‐induced gastric mucosal damage – More to do in further research. Authors' reply
di: Nina Løn, et al.
Pubblicazione: (2024)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Letter: Enhancing gastric cancer prevention—The need for a comprehensive three‐tier emergency management strategy. Authors' reply
di: Irene Ligato, et al.
Pubblicazione: (2024)

Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2‐F3 fibrosis. Authors' reply
di: Stuart McPherson, et al.
Pubblicazione: (2024)

Editorial: Terlipressin and MDRO colonisation in cirrhosis—Is there a causal link?
di: Luciano Revelli, et al.
Pubblicazione: (2024)

Letter: Potential confounders might exaggerate the risk of rheumatoid arthritis in patients with microscopic colitis—Authors' reply
di: David Bergman, et al.
Pubblicazione: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy—Authors' reply
di: Annalisa Schiepatti, et al.
Pubblicazione: (2024)

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes
di: Lana Bridi, et al.
Pubblicazione: (2024)

Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Thioguanine, an under‐utilised option in inflammatory bowel disease? Authors' reply
di: Abhinav Vasudevan, et al.
Pubblicazione: (2024)

Letter: Modifying the Mayo endoscopic subscore for improved prognostic insights. Authors' reply
di: Matthias Lenfant, et al.
Pubblicazione: (2024)

Letter: Dietary emulsifiers and intestinal health—The beginning of an evolving story: Authors’ reply
di: Jessica A. Fitzpatrick, et al.
Pubblicazione: (2024)

Repeatability of vibration‐controlled transient elastography versus magnetic resonance elastography in patients with cirrhosis: A prospective study
di: Harris Siddiqi, et al.
Pubblicazione: (2024)

Review article: Recent advances in ascites and acute kidney injury management in cirrhosis
di: Danielle Adebayo, et al.
Pubblicazione: (2024)

Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply
di: Eiichi Ogawa
Pubblicazione: (2024)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
di: Philippe Sultanik, et al.
Pubblicazione: (2024)

Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
di: Lisa Sandmann, et al.
Pubblicazione: (2024)

Non‐selective beta‐blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real‐world study
di: Rahul Kumar, et al.
Pubblicazione: (2024)

Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'
di: Francesco Calabrese, et al.
Pubblicazione: (2024)

Letter: Social work and clinical synergy—Optimizing health interventions for elderly DGBI populations: Authors' reply
di: Ami D. Sperber, et al.
Pubblicazione: (2024)

Letter: Intestinal permeability accounting for ongoing gastrointestinal symptoms following endoscopic remission in IBD—Authors' reply
di: Arta Aliu, et al.
Pubblicazione: (2024)